NASDAQ: AGMBAgomab Therapeutics Nv Stock
$11.05+0.35 (+3.27%)
Updated Apr 24, 2026
AGMB Price
$11.05
Fair Value Price
N/A
Market Cap
$538.54M
52 Week Low
$9.00
52 Week High
$17.45
P/E
-0.07x
P/B
3.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$61M
Beta
1.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AGMB Overview
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AGMB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AGMB
Ranked#141 of 467
Ranked#141 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.57 | A | |
| $196.52 | A | |
| $7.54 | A |
Be the first to know about important AGMB news, forecast changes, insider trades & much more!
AGMB News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AGMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AGMB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AGMB is good value based on its book value relative to its share price (3.54x), compared to the US Biotechnology industry average (4.93x)
P/B vs Industry Valuation
AGMB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AGMB due diligence checks available for Premium users.
Valuation
AGMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
20.3x
Market
35.57x
AGMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.54x
Industry
4.93x
AGMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AGMB's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.5M
Profit Margin
0%
AGMB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$180.8M
Liabilities
$26.8M
Debt to equity
0.17
AGMB's short-term assets ($140.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AGMB's short-term assets ($140.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AGMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
-$35.3M
Financing
-$40.0k
AGMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AGMB vs Biotech Stocks
Agomab Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.